Results 231 to 240 of about 70,385 (287)
Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis
Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab +3 more
wiley +1 more source
Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.ABSTRACT There is a need to better understand the indications and safety profiles for therapeutic plasma exchange (TPE) in children. We aimed to assess pediatric TPE practice at a large academic center by retrospective chart review from 2011 to 2022. Patient demographics and clinical information including American Society for Apheresis (ASFA) category ...
Benjamin C. Lee +4 more
wiley +1 more source
Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.Schematic illustration on a therapeutic strategy wherein engineered extracellular vesicles (EVs) are delivered intranasally and specifically target pericytes. In a model of chronic cerebral hypoperfusion (BCAS), this targeted approach preserves cerebral blood flow, reinforces blood‐brain barrier (BBB) integrity, stabilizes the neurovascular unit (NVU),
Weiwei Shen +11 more
wiley +1 more source
Biological Drivers of IMiD‐Induced Peripheral Neuropathy in Multiple Myeloma
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, making treatment‐related side effects increasingly important.
Sina A. Beer +2 more
wiley +1 more source
Multiple Sclerosis Journal, 2015 Whether or not recurrent tumefactive demyelinating lesions are a unique form of CNS demyelinating disease or part of the continuum of multiple sclerosis is a question raised by the case report on which this commentary is based.
Brian G Weinshenker
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Superantigens in demyelinating disease
Springer Seminars in Immunopathology, 1996Autoreactive T cells are part of the normal lymphocyte repertoire of healthy individuals [4]. In the immune system of healthy individuals, potent regulatory mechanisms control T and B cell tolerance to self antigens. While genetic factors influence susceptibility to autoimmunity in humans and experimental animals, environmental factors contribute to ...
S, Brocke, C, Piercy, L, Steinman
openaire +2 more sources
Demyelinating diseases in Asia
Current Opinion in Neurology, 2016The present review aims to discuss the recent advances in inflammatory demyelinating diseases of the central nervous system in Asia.Prevalence of multiple sclerosis (MS) in Asia is lower than that in Western countries, although it has been increasing recently.
Hirofumi, Ochi, Kazuo, Fujihara
openaire +2 more sources
Pathology of Demyelinating Diseases
Annual Review of Pathology: Mechanisms of Disease, 2012There has been significant progress in our understanding of the pathology and pathogenesis of central nervous system inflammatory demyelinating diseases. Neuropathological studies have provided fundamental new insights into the pathogenesis of these disorders and have led to major advances in our understanding of multiple sclerosis (MS) heterogeneity ...
Bogdan F Gh, Popescu +1 more
openaire +2 more sources